Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0311930 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Kazuyoshi Ohkawa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Letrozole, Liver Cirrhosis, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Towa Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Treatment strategies for preventing liver fibrosis have not yet been established. Letrozole, widely used for breast cancer, has recently been reported to suppress liver fibrosis in murine models. Therefore, we aimed to validate the suppressive effects of letrozole on liver fibrosis in the clinical setting. From 2006 to 2020, 23 consecutive patients who received continuous letrozole treatment for 24 months or more and had a liver fibrosis marker FIB-4 index of ≥ 2.30, were included. Forty-three patients who underwent anastrozole treatment for 24 months or more and had a liver fibrosis marker FIB-4 index of ≥ 2.30, were also included as controls. The Fisher exact, chi-square, unpaired Student t , and paired Student t test were used to analyze the data. The patient characteristics were similar between the letrozole- and anastrozole-treated patient groups. Among the letrozole-treated patients, the mean FIB-4 index tended to decline during letrozole treatment; a significant decrease was observed at 18 and 24 months compared with the baseline values (p = 0.044 and p = 0.013). In addition, the mean aspartate aminotransferase-to-platelet ratio index (APRI) decreased during letrozole treatment; the values at 18 and 24 months were significantly lower than those at baseline (p = 0.024 and p = 0.026). In contrast, among anastrozole-treated patients, the mean FIB-4 index and APRI did not change during anastrozole treatment. When changes in the FIB-4 index were further examined in a limited number of patients with a FIB-4 index ≥ 2.67, a significant reduction in the FIB-4 index at 24 months compared with baseline was also observed in letrozole-treated patients (p = 0.023), but not in anastrozole-treated patients. In conclusion, our findings support a possible suppressive effect of letrozole on liver fibrosis in the clinical setting. Further studies are required to better understand the pharmacological effects of letrozole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Clinical Research and Genetic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Next-Generation Precision Medicine Research Center, Osaka International Cancer Institute, Osaka, Japan.
- Research & Development Department, Towa Pharmaceutical Co., Ltd., Kadoma, Osaka, Japan.
- Scientific Research and Business Development Department, Protosera, Inc., Settsu, Osaka, Japan.
- Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Kazuyoshi Ohkawa, Kenji Ikezawa
Förderung
- Towa Pharmaceutical Co., Ltd
Zitieren
APA
Ohkawa, K., Nakabori, T., Mukai, K., Kozumi, K., Urabe, M., Kai, Y., Takada, R., Ikezawa, K., Yamaguchi, Y., Nagao, T., Enomoto, H., Tachiki, H., Higuchi, A., Watanabe, N., & Nakayama, T. (2024). Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study. PLOS ONE. https://doi.org/10.1371/journal.pone.0311930
Vancouver
Ohkawa K, Nakabori T, Mukai K, Kozumi K, Urabe M, Kai Y, et al. Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study. PLOS ONE. 2024. doi:10.1371/journal.pone.0311930
BibTeX
@article{Ohkawa2024,
author = {Ohkawa, Kazuyoshi and Nakabori, Tasuku and Mukai, Kaori and Kozumi, Kazuhiro and Urabe, Makiko and Kai, Yugo and Takada, Ryoji and Ikezawa, Kenji and Yamaguchi, Yuko and Nagao, Takuya and Enomoto, Hatsune and Tachiki, Hidehisa and Higuchi, Ayako and Watanabe, Noriyuki and Nakayama, Takahiro},
title = {Clinical validation of the suppressive impact of letrozole on liver fibrosis in patients with breast cancer undergoing continuous letrozole administration: A retrospective study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0311930}
}
EUVIMED